{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:32Z","timestamp":1793191772018,"version":"4.5.0"},"reference-count":48,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2115777","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T14:29:40Z","timestamp":1661178580000},"page":"1068-1075","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-4028","authenticated-orcid":false,"given":"Maria Elisa","family":"Mancuso","sequence":"first","affiliation":[{"name":"Centre for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Center for Bleeding Disorders, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pochopien","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Aball\u00e9a","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-8571","authenticated-orcid":false,"given":"Aleksandra","family":"Drzewiecka","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-8599","authenticated-orcid":false,"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum Ltd, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Nazir","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum Ltd, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-3953","authenticated-orcid":false,"given":"Francis","family":"Fatoye","sequence":"additional","affiliation":[{"name":"Faculty of Health and Education, Manchester Metropolitan University, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.05.001"},{"key":"e_1_3_6_3_1","unstructured":"National Hemophilia Foundation. Fast facts. 2020. [cited 2020 May]. Available from: https:\/\/www.hemophilia.org\/About-Us\/Fast-Facts."},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12504"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0660-y"},{"key":"e_1_3_6_6_1","unstructured":"World Federation of Hemophilia. Complications of hemophilia. 2012. [cited 2020 April]; Available from: http:\/\/www1.wfh.org\/publications\/files\/pdf-1499.pdf."},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13027"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-016-0785-2"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02791.x"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-050435"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12092"},{"issue":"6","key":"e_1_3_6_12_1","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort L","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W, et\u00a0al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479\u2013486.","journal-title":"Blood Transfus"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2018.065"},{"key":"e_1_3_6_14_1","unstructured":"European Medicines Agency. Elocta (rFVIIIFc) summary of product characteristics. 2019. [cited 2020 May]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elocta-epar-product-information_en.pdf."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13953"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01599-1"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1405816"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-0158-8"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01200-2"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718799997"},{"key":"e_1_3_6_23_1","unstructured":"Roche Pharma AG. Hemlibra\u00ae summary of product characteristics. 2019. [cited 2020 March]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf."},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S288283"},{"key":"e_1_3_6_25_1","unstructured":"Genentech. Hemlibra dosing calculator. 2020. [cited 2020 March]. Available from: https:\/\/www.hemlibra.com\/hcp\/dosing-administration\/dosing-calculator.html."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_3_6_28_1","volume-title":"Essentials of pharmacoeconomics","author":"KL R.","year":"2009","unstructured":"KL R. Essentials of pharmacoeconomics. Chapter 4. Philadelphia (PA): Lippincott Williams & Wilkins; 2009."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13404"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1175-5"},{"issue":"1","key":"e_1_3_6_31_1","first-page":"19","article-title":"Economic impact of hemophilia type A and B in Mexico","volume":"152","author":"Carlos-Rivera F","year":"2016","unstructured":"Carlos-Rivera F, Gasca-Pineda R, Majluf-Cruz A, et\u00a0al. Economic impact of hemophilia type A and B in Mexico. Gac Med Mex. 2016;152(1):19\u201329.","journal-title":"Gac Med Mex"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462316000544"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S16670"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13185"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0588-z"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.01.025"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_701_16"},{"issue":"3","key":"e_1_3_6_38_1","first-page":"s567","article-title":"The social burden and quality of life of patients with haemophilia in Italy","volume":"12","author":"Kodra Y","year":"2014","unstructured":"Kodra Y, Cavazza M, Schieppati A, et\u00a0al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014;12(Suppl 3):s567\u2013s575.","journal-title":"Blood Transfus"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3398-x"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1669614"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2014.02.008"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjdsi.2016.04.004"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13220"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.7.632"},{"key":"e_1_3_6_45_1","unstructured":"Agency EM. Advate summary of product characteristics. 2018. [cited 2022 June]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/advate-epar-product-information_en.pdf."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3401822"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14143"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14129"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2115777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:23:49Z","timestamp":1729164229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2115777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2115777"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2115777","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}